Partnership / Collaboration · MENA · Announced 12 Jul 2026
Northwest Biotherapeutics → SPIMACO
Partnership / Collaboration deal between Northwest Biotherapeutics (United States) and SPIMACO (Saudi Arabia), covering DCVax®-L, announced 12 Jul 2026. Value: Undisclosed.
Parties: Northwest Biotherapeutics, Inc. (United States) → SPIMACO (Saudi Arabia)
- Deal type
- Partnership / Collaboration
- Value
- Undisclosed
- Territory
- Saudi Arabia first; expandable to GCC
- Therapeutic area
- Oncology
- Asset
- DCVax®-L — autologous dendritic-cell (personalized) active immunotherapy
- Announced
- 12 Jul 2026
Our analysis
Why this matters — but read the status carefully.
DCVax-L is a genuinely novel modality: a personalized (autologous) dendritic-cell immunotherapy , made from each patient's own immune cells and tumor material, for glioblastoma — one of the deadliest cancers, with almost no effective options.
The full analysis is free to read with a work email on this page.
Source: Northwest Biotherapeutics press release / PR Newswire (via BioSpace)